Teva sues Watson, others over proposed US Azilect generic
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has filed against three generics makers in US, including Watson Pharmaceuticals, alleging infringement related to proposed generic versions of the Parkinson's disease treatment Azilect (rasagiline mesylate).